New drug targets aggressive brain tumors in phase II trial

NCT ID NCT04559230

Recruiting now Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called sacituzumab govitecan in 32 adults whose glioblastoma (a type of brain cancer) has returned after standard treatment. The drug targets a protein called Trop-2 found on tumor cells. The main goal is to see if patients live longer compared to past results with the older drug lomustine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States
Texas Oncology Austin
RECRUITING

Austin, Texas, 78705, United States
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.